- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
TeraRecon Launches AI-Driven Neuroimaging Platform
TeraRecon Neuro reportedly offers six automated and customizable computed tomography (CT) perfusion maps that facilitate assessment of brain function in hemorrhagic and ischemic neurological cases.
A new artificial intelligence (AI)-powered neuroimaging platform may offer adjunctive benefits for timely assessment and treatment decisions in neurovascular emergencies.
One of the benefits of TeraRecon Neuro is automated screening for challenging cases involving possible intracerebral hemorrhages (ICHs) and large vessel occlusions (LVOs), according to TeraRecon, the manufacturer of the platform.
The company said TeraRecon Neuro enables radiologists to modify the platform’s algorithm to optimize AI outputs. TeraRecon noted the TeraRecon Neuro platform, viewable on diagnostic desktop viewers and via a mobile app, also enhances the assessment of brain function with six customizable computed tomography (CT) perfusion maps.
“We believe the best use case scenario is not autonomous AI, but rather expert clinical supervision that is augmented by AI-driven insights. TeraRecon Neuro was designed to accommodate all care team members and workflows, while simultaneously maintaining standardization across the care continuum to ensure timely delivery of coordinated care for numerous neurovascular emergencies,” noted Dan McSweeney, the president of TeraRecon.
FDA Clears AI-Powered Ultrasound Software for Cardiac Amyloidosis Detection
November 20th 2024The AI-enabled EchoGo® Amyloidosis software for echocardiography has reportedly demonstrated an 84.5 percent sensitivity rate for diagnosing cardiac amyloidosis in heart failure patients 65 years of age and older.
